VioQuest Pharmaceuticals, Inc. (VOQP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VioQuest Pharmaceuticals, Inc. (VOQP) trades at $0.003 with AI Score 44/100 (Grade C). VioQuest Pharmaceuticals, Inc. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for VOQP: VOQP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VOQP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VOQP: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
VioQuest Pharmaceuticals, Inc. (VOQP) Healthcare & Pipeline Overview
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical entity developing clinical-stage drug therapies for oncology and infectious diseases, including Xyfid for hand-foot syndrome, VQD-002 for cancer, and Lenocta for solid tumors. Additionally, it offers chiral products and custom synthesis services to the pharmaceutical industry.
What Is the Investment Thesis for VOQP?
VioQuest Pharmaceuticals, Inc. presents an investment profile centered on its clinical-stage biopharmaceutical pipeline and specialized service offerings. The company's core value drivers are its three primary drug candidates: Xyfid, advancing for hand-foot syndrome; VQD-002, a nucleoside analog in Phase I for cancer; and Lenocta, a small molecule in Phase IIa for solid tumors including melanoma and renal cell carcinoma. Successful progression through clinical trials and eventual regulatory approval for any of these compounds would represent significant growth catalysts, potentially unlocking substantial market value in oncology and supportive care. Additionally, the company's provision of chiral products, specialized technology, and bespoke synthesis development services to pharmaceutical and fine chemical companies offers a distinct, albeit smaller, revenue stream that leverages its scientific expertise. However, the investment carries substantial risks, notably its extremely small market capitalization of approximately $14,719 and its trading on the OTC Other tier, indicating significant financial and operational challenges. The company's limited employee base of three and the inherent opacity of its current activities, as noted by AI insight, further underscore the speculative nature of this opportunity. Investors must weigh the potential upside of pipeline success against the inherent risks of a micro-cap, OTC-listed biopharmaceutical entity with limited transparency.
Based on FMP financials and quantitative analysis
VOQP Key Highlights
Market capitalization of approximately $14,719, indicating an extremely small-cap valuation.
- Primary product, Xyfid, is currently being advanced for the management and prevention of hand-foot syndrome.
- Pipeline includes VQD-002, a nucleoside analog, presently in Phase I clinical trials for cancer treatment.
- Lenocta, a small molecule, is progressing through Phase IIa clinical studies for melanoma, renal cell carcinoma, and other solid tumors.
- Operates with a lean team of 3 employees, headquartered in Basking Ridge, US, and trades on the OTC Other tier.
Who Are VOQP's Competitors?
VOQP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VOQP's Key Strengths?
Clinical-stage pipeline with three distinct drug candidates (Xyfid, VQD-002, Lenocta) targeting oncology and infectious diseases.
- Dual business model combining drug development with specialized chemical synthesis services, offering diversified revenue potential.
- Specialized expertise in developing complex drug therapies and providing niche chemical products.
- Established in 2000, indicating a foundational history in the biopharmaceutical sector.
What Are VOQP's Weaknesses?
Extremely small market capitalization of approximately $14,719, indicating significant financial challenges.
- Very limited employee base of 3, potentially constraining operational capacity and scalability.
- Trading on the OTC Other tier, associated with low transparency and high investment risk.
- Unknown disclosure status, making it difficult for investors to access current financial and operational information.
What Could Drive VOQP Stock Higher?
Clinical trial progression for Xyfid for the management and prevention of hand-foot syndrome.
- Phase I clinical trial progression for VQD-002 as a nucleoside analog for cancer treatment.
- Phase IIa clinical trial progression for Lenocta for indications including melanoma, renal cell carcinoma, and other solid tumors.
- Potential for new service contracts or expanded client engagements for its chiral products and bespoke synthesis development services.
What Are the Key Risks for VOQP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant financial and operational challenges due to an extremely small market capitalization and OTC Other listing.
- Clinical trial failures or delays for Xyfid, VQD-002, or Lenocta, which could halt drug development.
- Intense competition from larger, better-funded biopharmaceutical companies with more extensive resources.
- Regulatory hurdles and prolonged approval processes for its drug candidates, impacting time to market.
- Limited transparency and liquidity associated with OTC Other tier trading, posing challenges for investors.
What Are the Growth Opportunities for VOQP?
- Advancement of Xyfid for Hand-Foot Syndrome: The successful progression and eventual commercialization of Xyfid for the management and prevention of hand-foot syndrome represents a significant growth opportunity. Hand-foot syndrome is a common and debilitating side effect of several chemotherapy agents, impacting patient quality of life and treatment adherence. The global market for supportive care in oncology, including symptom management, is substantial and growing, driven by increasing cancer incidence and advanced treatment options. A novel, effective therapy like Xyfid could capture a meaningful share of this market, providing a crucial solution for patients and clinicians. The timeline for this opportunity depends on the successful completion of ongoing clinical trials and subsequent regulatory approvals.
- Progression of VQD-002 in Oncology: VQD-002, a nucleoside analog currently in Phase I clinical trials for cancer treatment, offers a long-term growth avenue. The oncology market is one of the largest and fastest-growing therapeutic areas globally, with a continuous demand for innovative therapies. Nucleoside analogs have a proven track record in cancer treatment, and a successful development path for VQD-002 could position VioQuest to address various unmet needs within this vast market. While Phase I is an early stage, positive results and subsequent advancement to later phases would significantly de-risk the compound and attract further investment or partnership opportunities, potentially leading to a substantial market presence in the future.
- Development of Lenocta for Solid Tumors: Lenocta, a small molecule inhibiting protein tyrosine phosphatases, is progressing through Phase IIa clinical studies for indications such as melanoma, renal cell carcinoma, and other solid tumors. The market for solid tumor treatments, particularly in difficult-to-treat cancers like melanoma and renal cell carcinoma, is highly lucrative and continues to expand with advancements in targeted therapies and immunotherapies. A successful outcome in Phase IIa and subsequent pivotal trials could position Lenocta as a valuable therapeutic option. Its mechanism of action, targeting protein tyrosine phosphatases, offers a differentiated approach that could provide a competitive advantage in specific patient populations, driving future revenue growth.
- Expansion of Chiral Products and Synthesis Services: Beyond its drug pipeline, VioQuest's offering of chiral products, specialized technology, and bespoke synthesis development services presents a stable, albeit smaller, growth opportunity. The pharmaceutical and fine chemical industries consistently require specialized chemical synthesis capabilities and high-purity chiral intermediates for their research and development, as well as manufacturing processes. As drug discovery becomes more complex, the demand for outsourced, specialized chemical services is expected to grow. VioQuest can leverage its scientific expertise and infrastructure to expand its client base and service portfolio, providing a more immediate and predictable revenue stream compared to the long development cycles of drug candidates.
- Strategic Collaborations and Partnerships: Given VioQuest's small size and early-stage pipeline, forming strategic collaborations or partnerships represents a crucial growth opportunity. Such alliances could provide necessary funding, access to larger development and commercialization infrastructures, and broader market reach. Larger pharmaceutical companies often seek to license or acquire promising early-stage assets to replenish their pipelines. A successful partnership for Xyfid, VQD-002, or Lenocta could accelerate their development, mitigate financial risks for VioQuest, and provide significant non-dilutive capital or milestone payments. This strategy is common in the biotechnology sector and could be pivotal for VioQuest's long-term viability and market penetration.
What Are VOQP's Competitive Advantages?
- Proprietary clinical-stage drug candidates (Xyfid, VQD-002, Lenocta) targeting specific therapeutic areas.
- Specialized scientific expertise in oncology, infectious diseases, and complex chemical synthesis.
- Intellectual property surrounding its drug pipeline and unique chemical processes.
- Niche market positioning in providing chiral products and bespoke synthesis services to the pharmaceutical and fine chemical industries.
What Does VOQP Do?
VioQuest Pharmaceuticals, Inc., established in 2000 and headquartered in Basking Ridge, New Jersey, operates as a biopharmaceutical entity dedicated to the acquisition, development, and commercialization of clinical-stage drug therapies. The company strategically focuses its efforts on critical therapeutic areas, specifically oncology and infectious diseases, addressing significant unmet medical needs. Its pipeline features several key drug candidates, each targeting distinct conditions. A primary product in its portfolio is Xyfid, which is actively being advanced through clinical stages for both the management and prevention of hand-foot syndrome, a debilitating side effect often associated with certain chemotherapy treatments. Beyond Xyfid, VioQuest's developmental pipeline includes VQD-002, a nucleoside analog. This compound is currently undergoing Phase I clinical trials, exploring its potential as a novel treatment for various forms of cancer. Another significant asset is Lenocta, a small molecule designed to selectively inhibit a range of protein tyrosine phosphatases. Lenocta is progressing through Phase IIa clinical studies, investigating its efficacy across multiple indications, including melanoma, renal cell carcinoma, and other solid tumors. These drug candidates represent the core of VioQuest's long-term value proposition in the biopharmaceutical space. In addition to its therapeutic drug development endeavors, VioQuest Pharmaceuticals diversifies its operations by offering specialized services to the broader pharmaceutical and fine chemical industries. These services encompass the provision of chiral products, which are crucial for synthesizing specific drug enantiomers, along with specialized technology solutions and bespoke synthesis development services. These offerings cater to companies at various stages of their product lifecycles, providing a supplementary revenue stream and leveraging the company's scientific expertise beyond its internal drug pipeline. This dual operational focus positions VioQuest as a unique, albeit small, player in the competitive healthcare sector.
What Products and Services Does VOQP Offer?
- Develops clinical-stage drug therapies for oncology and infectious diseases.
- Advances Xyfid for the management and prevention of hand-foot syndrome.
- Conducts Phase I clinical trials for VQD-002, a nucleoside analog for cancer treatment.
- Progresses Lenocta through Phase IIa clinical studies for melanoma, renal cell carcinoma, and other solid tumors.
- Offers chiral products to pharmaceutical and fine chemical companies.
- Provides specialized technology development services.
- Delivers bespoke synthesis development services to support product lifecycles in the chemical industry.
How Does VOQP Make Money?
- Potential future revenue generation from the commercialization of its clinical-stage drug therapies upon regulatory approval.
- Generates revenue from the sale of specialized chiral products to other pharmaceutical and fine chemical companies.
- Earns income by providing specialized technology development services to industry clients.
- Secures revenue through bespoke synthesis development services, catering to specific client needs in chemical manufacturing and R&D.
What Industry Does VOQP Operate In?
VioQuest Pharmaceuticals, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on drug development for oncology and infectious diseases. This sector is characterized by lengthy and capital-intensive research and development cycles, high regulatory hurdles, and significant risks associated with clinical trial outcomes. The broader biopharmaceutical market is driven by an aging global population, increasing prevalence of chronic diseases, and continuous scientific advancements. VioQuest, as a small player with a clinical-stage pipeline, competes against much larger, well-funded pharmaceutical giants and numerous other biotech firms. Its dual approach of drug development alongside specialized chemical synthesis services positions it uniquely, aiming to generate revenue from both potential future drug sales and immediate service provision to the pharmaceutical and fine chemical sectors, a niche within the broader industry landscape.
Who Are VOQP's Key Customers?
- Future patients suffering from hand-foot syndrome (via Xyfid).
- Future cancer patients (via VQD-002 and Lenocta).
- Pharmaceutical companies requiring chiral products, specialized technology, or custom synthesis services.
- Fine chemical companies seeking specialized chemical development and manufacturing support.
Company Profile
VioQuest Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Basking Ridge, US. The company is led by CEO Mark D. Dacko. VOQP has traded publicly since 1994.
VOQP Valuation & Market Position
Relative to its peer group, VOQP's quantitative score of 44/100 is below the peer average of 76/100.
Financial Health
VioQuest Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VOQP Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in VioQuest's upcoming clinical trials, indicating belief in positive outcomes.
- Community sentiment has shifted positively as discussions around innovative therapies gain traction, reflecting optimism.
- Analysts have noted increasing interest in the oncology sector, which could benefit VioQuest's pipeline of cancer treatments.
- Recent partnerships and collaborations have sparked enthusiasm, highlighting VioQuest's potential for growth and market expansion.
Bear Case
- Concerns about the lengthy timelines for clinical trial results have led to skepticism among some investors, impacting sentiment.
- Market perception remains cautious due to the competitive landscape in pharmaceuticals, where many players are vying for attention.
- Recent earnings calls revealed challenges in funding, raising questions about VioQuest's ability to sustain operations without additional capital.
- Negative social sentiment has surfaced regarding the company's ability to deliver on promises, causing some traders to reconsider their positions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VOQP Latest News
No recent news available for VOQP.
VOQP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VOQP.
Price Targets
Wall Street price target analysis for VOQP.
VOQP MoonshotScore
What does this score mean?
The MoonshotScore rates VOQP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mark D. Dacko
Managing Director
Unknown
Track Record: Unknown
VOQP OTC Market Information
VioQuest Pharmaceuticals, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Companies listed on OTC Other typically do not meet the minimum disclosure or financial requirements for higher tiers like OTCQX or OTCQB, nor do they qualify for listing on major exchanges such as the NYSE or NASDAQ. This tier is characterized by a significant lack of transparency, as companies are often not required to file financial reports with the SEC or any other regulatory body, making it challenging for investors to access reliable, current information.
- OTC Tier: OTC Other
- Lack of transparency due to unknown disclosure status, hindering informed investment decisions.
- Extremely low liquidity and wide bid-ask spreads, making it difficult to trade shares efficiently.
- Potential for price manipulation given the low market capitalization and limited oversight.
- Significant financial and operational challenges, as indicated by the micro-cap valuation and OTC Other tier.
- High risk of delisting or cessation of trading if the company fails to maintain even minimal operational activity.
- Verify any available recent company announcements or press releases, however infrequent.
- Attempt to locate any historical financial filings, even if unaudited or outdated.
- Assess the current operational status of its clinical pipeline and service offerings.
- Investigate the background and current involvement of its leadership, particularly Mark D. Dacko.
- Understand the company's current funding situation and burn rate, if ascertainable.
- Evaluate the intellectual property status of its drug candidates.
- Research any past regulatory actions or compliance issues.
- Established in 2000, indicating a history of operation.
- Defined corporate headquarters in Basking Ridge, New Jersey.
- Specific clinical-stage drug candidates (Xyfid, VQD-002, Lenocta) with stated trial phases.
- Offers tangible services like chiral products and custom synthesis development.
- Identified leadership in Mark D. Dacko, managing a small team.
VOQP Healthcare Stock FAQ
What does the AI Score mean for VOQP?
VOQP holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing clinical-stage drug therapies for oncology and infectious diseases, with pipeline candidates like Xyfid, VQD-002 …
What does VioQuest Pharmaceuticals, Inc. do?
VioQuest Pharmaceuticals, Inc. operates as a biopharmaceutical company primarily focused on the acquisition, development, and marketing of clinical-stage drug therapies for oncology and infectious diseases.
How does VioQuest Pharmaceuticals, Inc. navigate regulatory approval processes for its drug candidates?
VioQuest Pharmaceuticals, Inc., as a biopharmaceutical company, must navigate complex regulatory approval processes, primarily with agencies like the U.S. Food and Drug Administration (FDA), for its drug candidates such as Xyfid, VQD-002, and Lenocta. The company's strategy involves progressing its compounds through distinct clinical trial phases—Phase I, Phase IIa, and future pivotal trials—to demonstrate safety and efficacy.
What are the main risks for VOQP given its OTC Other listing?
Investing in VioQuest Pharmaceuticals, Inc. (VOQP) carries significant risks, particularly due to its trading on the OTC Other tier. This classification implies a substantial lack of transparency, as the company's disclosure status is unknown, meaning investors have limited access to reliable financial reports or operational updates. This opacity makes informed decision-making challenging.
What revenue streams does VioQuest Pharmaceuticals, Inc. currently have?
VioQuest Pharmaceuticals, Inc. generates revenue through a dual business model. Its primary long-term potential revenue stream is derived from the future commercialization of its clinical-stage drug therapies, including Xyfid for hand-foot syndrome, VQD-002 for cancer, and Lenocta for solid tumors, upon successful completion of clinical trials and regulatory approvals.
What are the key factors to evaluate for VOQP?
VioQuest Pharmaceuticals, Inc. (VOQP) holds an AI score of 44/100 (low). presents an investment profile centered on its clinical-stage biopharmaceutical pipeline and specialized service offerings. Not financial advice.
How frequently does VOQP data refresh on this page?
VOQP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VOQP's recent stock price performance?
VioQuest Pharmaceuticals, Inc. (VOQP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clinical-stage pipeline with three distinct drug candidates (Xyfid, VQD-002, Lenocta) targeting oncology and infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VOQP overvalued or undervalued right now?
VioQuest Pharmaceuticals, Inc. (VOQP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Reliance on provided business description for current activities, as external AI insight noted 'current activities are unclear'.
- Limited financial data beyond market capitalization and stock price was available.
- Detailed CEO background and track record were not provided in the source data.